Yuflyma 40 mg injection

Yuflyma is a high-concentration, citrate-free biosimilar of adalimumab, used to treat various inflammatory conditions such as rheumatoid arthritis and Crohn's disease. Developed by the South Korean biopharmaceutical giant Celltrion, Inc., the brand represents a significant advancement in the biosimilar landscape. Originally invented and developed in South Korea, the product has gained global regulatory approvals, including from the FDA and the European Commission.

Manufacturing for Yuflyma is spread across several locations to meet global demand. While Celltrion operates large-scale facilities in Incheon, South Korea, production for specific markets and delivery systems (like the autoinjector pens) has also been associated with manufacturing lines in Europe, specifically in Hungary and Belgium. This diverse supply chain ensures the medicine's availability across North America, Europe, and Asia.

The brand is owned by Celltrion, Inc., a leader in the global biopharmaceutical industry headquartered in Incheon, South Korea. Celltrion manages its international presence through various subsidiaries, such as Celltrion USA for the American market and Celltrion Healthcare for global distribution. As of 2026, Celltrion remains the ultimate owner, continuing to expand its portfolio of biosimilars and innovative biologics to provide high-quality, accessible treatment options worldwide.